ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

172
Analysis
Health CareChina
CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.
more
Refresh
15 Jan 2020 10:06

Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do

2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...

Logo
582 Views
Share
08 Jan 2020 17:38

2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
657 Views
Share
bullishSmartkarma
12 Sep 2019 15:33

Hong Kong IPO Analytics - Regular Cornerstone Investors and Track Record

At the beginning of this year, we at Aequitas Research, wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Share
05 Aug 2019 11:11

HK IPO Analytics 1H2019: MS and CICC Stand Out

At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Logo
600 Views
Share
28 Jul 2019 13:24

🇨🇳🇭🇰 That Was The Week That Was • China/Hong Kong 22nd-27th July 2019 @Smartkarma

TW3 CHINA/HONG KONG 22-27 JUNEThis TW3 covers China and Hong Kong and is a companion to the North Asian TW3 published earlier today.  The weight of...

Logo
567 Views
Share
x